Global Push to Slash Drug Prices Gains Momentum

Governments and health organizations worldwide are implementing aggressive new policies to dramatically lower the cost of essential medicines, from groundbreaking treatments for Alzheimer's disease to common diabetes drugs. This concerted effort aims to ease the financial burden on public health systems and patients by challenging traditional pharmaceutical pricing models.

In a landmark move, China has cut the price of the historic Alzheimer's drug Leqembi by approximately half, placing it on a new national insurance list to improve access for its 17 million patients [28069]. Similarly, the United States government, through Medicare, has begun direct price negotiations for 15 widely used prescription drugs, with significant reductions already secured for medications like Ozempic and Wegovy [13227][13349]. In one case, the cost of a typical dose of Ozempic is set to drop by 71% [13349].

The European Union is pursuing a structural solution, voting to shorten market exclusivity for new drugs from 10 to 8 years. This reform will allow cheaper generic versions to enter the market years sooner, aiming to lower overall healthcare costs across member states [23585]. Parallel to these governmental actions, international bodies are also securing deals. The United Nations International Children's Emergency Fund (UNICEF) has reached an agreement to lower the cost of a new malaria vaccine, a critical tool against one of the world's deadliest diseases for children [11414].

Even pharmaceutical companies are responding to pressure. Novo Nordisk has reduced the direct-to-consumer price for its popular weight-loss and diabetes drugs Wegovy and Ozempic by 30% for some patients [6544]. The trend underscores a global rebalancing act, where the need to reward drug innovation is being weighed against the urgent imperative to make treatments affordable and sustainable for public health systems [23585].